[
  {
    "ts": "2026-02-24T05:22:00+00:00",
    "headline": "Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China",
    "summary": "Hangzhou Sciwind Biosciences Co., Ltd. (\"Sciwind Biosciences\") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authoriz",
    "url": "https://finance.yahoo.com/news/sciwind-biosciences-partners-pfizer-china-052200785.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "89263c08-9b3b-3961-a20d-bc53eec6b6e5",
      "content": {
        "id": "89263c08-9b3b-3961-a20d-bc53eec6b6e5",
        "contentType": "STORY",
        "title": "Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China",
        "description": "",
        "summary": "Hangzhou Sciwind Biosciences Co., Ltd. (\"Sciwind Biosciences\") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer's global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authoriz",
        "pubDate": "2026-02-24T05:22:00Z",
        "displayTime": "2026-02-24T05:22:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/d5a19cbf687bead2b31810197f8acb16",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/aeiFdrqYdevlzaMwkjArQg--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/d5a19cbf687bead2b31810197f8acb16.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RaJRLl5hHvexkZ6yjmh3gQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/d5a19cbf687bead2b31810197f8acb16.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sciwind-biosciences-partners-pfizer-china-052200785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sciwind-biosciences-partners-pfizer-china-052200785.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T05:06:22+00:00",
    "headline": "Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results",
    "summary": "Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal BREAKWATER trial results for BRAFTOVI in metastatic colorectal cancer. Together, these developments highlight fresh activity in Pfizer's pipeline across both metabolic disease and oncology. For investors watching NYSE:PFE, these moves come with the stock trading around $27.06 and mixed longer term...",
    "url": "https://finance.yahoo.com/news/pfizer-pipeline-shifts-obesity-push-050622874.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "7a5af84c-826b-3b8e-a26d-271e0fdbf6e7",
      "content": {
        "id": "7a5af84c-826b-3b8e-a26d-271e0fdbf6e7",
        "contentType": "STORY",
        "title": "Pfizer Pipeline Shifts With Obesity Push And BREAKWATER Cancer Results",
        "description": "",
        "summary": "Pfizer (NYSE:PFE) has expanded its obesity drug ambitions with the acquisition of Metsera and more than 20 active clinical studies in weight management. The company also reported promising pivotal BREAKWATER trial results for BRAFTOVI in metastatic colorectal cancer. Together, these developments highlight fresh activity in Pfizer's pipeline across both metabolic disease and oncology. For investors watching NYSE:PFE, these moves come with the stock trading around $27.06 and mixed longer term...",
        "pubDate": "2026-02-24T05:06:22Z",
        "displayTime": "2026-02-24T05:06:22Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/QSfydsi7Q.1zNEN99DbEyw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hi2p7oczHh8yTJraqZcczg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/f7c3fa24d3150b866dc98f7b00648685.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pipeline-shifts-obesity-push-050622874.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-pipeline-shifts-obesity-push-050622874.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-02-24T11:05:28+00:00",
    "headline": "Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise",
    "summary": "Celcuity (NasdaqCM:CELC) has appointed Charles (Chip) R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in collaboration with Pfizer. Celcuity, trading at $105.15, has seen very large share price gains over the past year, with a 1 year return above 800% and a 3 year return above 800% as well. Short term moves have been more mixed, with a 0.6% return...",
    "url": "https://finance.yahoo.com/news/celcuity-adds-oncology-veteran-board-110528894.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "204a5c33-09f1-3ce1-a952-67b8149bb04b",
      "content": {
        "id": "204a5c33-09f1-3ce1-a952-67b8149bb04b",
        "contentType": "STORY",
        "title": "Celcuity Adds Oncology Veteran To Board As Gedatolisib Commercial Stakes Rise",
        "description": "",
        "summary": "Celcuity (NasdaqCM:CELC) has appointed Charles (Chip) R. Romp to its Board of Directors. Romp brings extensive oncology commercialization experience from senior roles at Seagen and Genentech. The appointment comes as Celcuity advances Gedatolisib in collaboration with Pfizer. Celcuity, trading at $105.15, has seen very large share price gains over the past year, with a 1 year return above 800% and a 3 year return above 800% as well. Short term moves have been more mixed, with a 0.6% return...",
        "pubDate": "2026-02-24T11:05:28Z",
        "displayTime": "2026-02-24T11:05:28Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/I2k3PKJsWIEX9xgEQz8JwQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tmSjpFKmBAT61w1lG5.BLQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/2b615bb0216a492e754128412857f305.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/celcuity-adds-oncology-veteran-board-110528894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/celcuity-adds-oncology-veteran-board-110528894.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "CELC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]